An interventional study of Administration of heparin after sheath insertion and Administration of heparin prior to sheath insertion in Coronary Angiography, Percutaneous Coronary Intervention and Radial Artery Occlusion, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Arterial Occlusive Diseases with a site in France — 4 open to participants now, 5 under way, none of them phase 3. Arterial Occlusive Diseases · France.
Among the 15 studies in Arterial Occlusive Diseases with a site in France, this one is the only one that started in 2025, is one of 8 with no phase, and was the 14th registered.
230 studies on the registry are indexed under Arterial Occlusive Diseases; 27 are open to participants now.
Browse Arterial Occlusive Diseases studies →4 of the 15 studies in Arterial Occlusive Diseases with a site in France are open now. Recruiting first, the newest first:
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Arterial Occlusive Diseases studies recruiting now, 13 (65%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 184 across 157 interventional studies indexed under Arterial Occlusive Diseases.
Median enrollment 775 across the 9 interventional studies, 332 across the 6 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 1 study filed under Arterial Occlusive Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Arterial Occlusive Diseases with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.
Prevention of radial occlusion relies on optimal hemostasis and anticoagulation. Previous studies have demonstrated a decrease incidence of radial artery occlusion through hemostasis at the puncture site using short-duration mechanical compression methods, guided by mean arterial pressure measurement, or clinical tests evaluating hand vascularization. Anticoagulation plays a central role in the prevention of radial occlusion. It is currently recommended to administer a systemic anticoagulant during a procedure using radial access. Despite the lack of consensus on the nature of the anticoagulant, an international survey showed that more than 90% of interventional cardiologists use unfractionated heparin. The intensity of anticoagulation is also associated with the risk of radial artery occlusion, with previous studies showing that the risk is reduced with the use of "high doses" (5000 IU or 75 IU/kg) compared to "low doses" (\<5000 IU or \<50 IU/kg). A randomized controlled trial did not show any difference between intravenous and intra-arterial heparin injection via the sheath. No studies have examined the timing of anticoagulant administration relative to sheath insertion. In current practice, anticoagulant administration is typically done after sheath insertion in the radial artery. This common practice likely stems from historical concerns about conversion to femoral access (which is now rare due to improved devices for radial puncture and less consequential due to vascular closure systems used in femoral access, significantly reducing hemorrhagic risk).
No data is currently available on the optimal timing of anticoagulant administration, despite the potential modification of its local effect if the sheath is already in place in the radial artery during the anticoagulant injection, obstructing the radial artery lumen. Our hypothesis is that intravenous anticoagulant administration before sheath insertion in the radial artery is more effective than administration after sheath insertion in patients undergoing percutaneous coronary intervention via radial access. The expected outcomes include a reduction in the incidence of radial artery occlusion after the procedure, leading to a decrease in potential complications (acute hand ischemia, failure of the access route during a subsequent procedure, inability to create an ipsilateral arteriovenous fistula).
The primary objective is to evaluate the impact of the timing (early or late) of intravenous anticoagulant administration on the risk of radial occlusion during a percutaneous coronary intervention via radial access.
This is a single-center, comparative, randomized, single-blind study with blinded evaluation of the primary endpoint.
After providing information and verifying eligibility criteria, the investigator will obtain the patient's free, informed, and written consent before any intervention, on the day the coronary angiography is scheduled. Consent will be obtained in the patient's hospital room (Cardiology Day Hospital or conventional hospitalization unit).
Randomization, in blocks of variable sizes, will be carried out by the investigator (or a delegate) after consent is signed and eligibility criteria are verified and before the percutaneous coronary intervention via radial access. Randomization assigns the subject's inclusion number and treatment group:
The percutaneous coronary intervention via radial access will be performed according to standard practice in the cardiac catheterization lab of our center. At the time of installation, the operator will palpate the radial pulse to ensure the feasibility of radial access. In the experimental group "early injection" of heparin, the injection will be done intravenously just before skin disinfection, approximately 5 minutes (± 3 minutes) before the puncture. In the control group "delayed injection", the injection will be done 5 minutes (± 3 minutes) after sheath insertion into the radial artery (protocol used in daily practice). If radial puncture fails, patients will be excluded from the primary endpoint analysis but will be followed up at 30 days for secondary endpoints. The heparin bolus dose will systematically be 50 IU/kg. At the end of the procedure, an ACT will be measured just before sheath removal, and hemostasis at the puncture site will be achieved using a TR-band® mechanical compression device. This will be placed before sheath removal and inflated with a syringe containing 15 cc of air for all patients. According to local protocol, mechanical compression is left in place for 2 hours before gradual deflation (removal of 2 cc every 15 minutes until complete deflation, bracelet left in place for 30 minutes post-deflation, then removed and replaced with a simple dressing). In case of additional coronary angioplasty, the heparin dose will be adjusted based on the angioplasty indication at the operators' discretion for a total dose of 0.7 to 1.0 mg/kg, aiming for an ACT > 250 ms.
At day 1, the following will be performed according to standard practice:
At day 30 (±7 days), patients will be contacted by phone specifically for the research by the investigators and co-investigators involved in the study. The telephone interview will consist of an inquiry for symptoms of radial occlusion or major cardiovascular events. If symptoms of radial occlusion are detected, the patient will be scheduled for a consultation with a clinical examination, pulse palpation, Barbeau maneuver, and upper limb arterial Doppler ultrasound on the same side as the radial puncture.
The primary endpoint is the rate of radial artery occlusion, as determined by Doppler ultrasound at day 1.
The secondary endpoints are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of heparin after sheath insertion
Procedure: Administration of heparin after sheath insertion
Administration of heparin prior to sheath insertion
Procedure: Administration of heparin prior to sheath insertion
Administration of heparin after sheath insertion
Administration of heparin prior to sheath insertion
Rate of radial artery occlusion
The primary endpoint is the rate of radial artery occlusion, as determined by Doppler ultrasound at day 1.
Time frame: Day 1
Rate of symptomatic radial artery occlusion (acute hand ischemia) on day 1
The rate of symptomatic radial artery occlusion (acute hand ischemia) on day 1. The rate of occlusion will be assessed through a thorough clinical examination on day 1 after the procedure, and if necessary, based on clinical findings, by an upper limb CT angiography. A telephone interview will also be conducted on day 30 to check for symptoms of symptomatic radial artery occlusion (signs of hand ischemia). If symptoms are present, the patient will be scheduled for a consultation with arterial Doppler ultrasound to confirm or rule out radial occlusion.
Time frame: Day1
Major cardiovascular events within the first 30 days following the percutaneous coronary intervention: cardiovascular death, myocardial infarction, and stroke.
Major cardiovascular events within the first 30 days following the percutaneous coronary intervention: cardiovascular death, myocardial infarction, and stroke. These events will be assessed during the visits on day 1 and day 30
Time frame: Day 30
Local and general hemorrhagic events
Local functional impact evaluated on day 30 by the presence of residual pain in the radial region or limited joint mobility.
Time frame: Day 30
Rate of radial puncture failure.
The rate of radial puncture failure.
Time frame: Day 0
Rate of all-cause mortality on day 30.
The occurrence of all-cause mortality on day 30.
Time frame: Day 30
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jan 2028, 31 months after the start.
Of 47 non-industry interventional studies with no phase under Arterial Occlusive Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 31 months is above that.
Counting every sponsor, half of 56 studies reached it within 27 months; a quarter within 14 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →